n(1)-methylnicotinamide has been researched along with Basedow Disease in 1 studies
N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filetti, S | 1 |
| Takai, NA | 1 |
| Rapoport, B | 1 |
1 other study available for n(1)-methylnicotinamide and Basedow Disease
| Article | Year |
|---|---|
Prevention by nicotinamide of desensitization to thyrotropin stimulation in cultured human thyroid cells.
Topics: Cells, Cultured; Cyclic AMP; Cycloheximide; Drug Synergism; Graves Disease; Humans; Kinetics; Niacin | 1981 |